CSIMarket Company Name, Ticker, Industry, else..
 
Invivyd Inc   (NASDAQ: IVVD)
 
Price: $0.8260 $-0.01 -1.078%
Day's High: $0.8269000053405762 Week Perf: -13.51 %
Day's Low: $ 0.79 30 Day Perf: 25.34 %
Volume (M): 1,959,172 52 Wk High: $ 3.07
Volume (M$): $ 0 52 Wk Avg: $1.51
Open: $0.82 52 Wk Low: $0.53



 Market Capitalization (Millions $) 265
 Shares Outstanding (Millions) 320
 Employees 122
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -107
 Cash Flow (TTM) (Millions $) 149
 Capital Exp. (TTM) (Millions $) 1

Business Description


Invivyd Inc is a technology startup that specializes in providing augmented reality (AR) solutions. The company focuses on developing innovative software and hardware products that enhance user experiences through AR technology. Their products allow users to interact with virtual elements in the real world, creating a blended reality experience. Invivyd Inc aims to revolutionize industries such as gaming, education, healthcare, and retail by leveraging the power of AR to create immersive and engaging experiences for users.


   Company Address: 209 Church Street New Haven 6510 CT
   Company Phone Number: 819-0080   Stock Exchange / Ticker: NASDAQ IVVD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ARMP        8.75% 
IBRX        0.37% 
MRNA        5.48% 
STRO   -1.86%    
TIL      0% 
VXRT   -1.3%    
• View Complete Report
   



Management Announcement

Invivyd Applauds FDAs Forward-Thinking Approach to COVID Vaccine Efficacy as It Defends Against Evolving Variants with PEMGARDA,

Published Wed, May 21 2025 1:30 PM UTC

Invivyd s Strong Stand Against Evolving COVID-19 Challenges and FDA s Progressive StepsIntroductionAs the landscape of COVID-19 continues to evolve with the emergence of new variants, companies and regulators alike must navigate the complexities of vaccine efficacy and therapeutic interventions. Invivyd, Inc. a biotechnology firm focused on developing monoclonal antibodies, ...
Clinical Study

Unyielding Defense Pemivibarts Sustained Efficacy Against Emerging SARS-CoV-2 Variants

Published Thu, Mar 13 2025 3:33 AM UTC

: The SARS-CoV-2 pandemic has been characterized by the virus s ability to mutate, leading to the emergence of new variants that challenge current therapeutic and prophylactic measures. Monoclonal antibodies (mAbs) have played a critical role in neutralizing these variants, providing an essential line of defense for vulnerable populations. Recent findings from Invivyd, Inc...
Clinical Study

Navigating the Path Toward Emergency Use A Balanced Look at Invivyds PEMGARDA Developments

Published Thu, Nov 14 2024 12:01 PM UTC

Invivyd, Inc. a biopharmaceutical company based in Waltham, Massachusetts, recently announced a significant publication in The New England Journal of Medicine (NEJM) that underscores a milestone in public health innovation. The publication is a Letter to the Editor that highlights the immunobridging pathway for PEMGARDA (pemivibart), leading to its Emergency Use Authorizat...
Product Service News

PEMGARDAs Enhanced EUA Implications for Invivyds Role in the Evolving Landscape of SARS-CoV-2 Variants

Published Tue, Oct 1 2024 11:01 AM UTC

In a recent announcement heralding the changing landscape of SARS-CoV-2 variants, Invivyd, Inc. unveiled significant updates surrounding the Emergency Use Authorization (EUA) for its monoclonal antibody therapy, PEMGARDA (pemivibart). The re-issued EUA Fact Sheet by the U.S. Food and Drug Administration (FDA) incorporates precise data on the efficacy of PEMGARDA against cur...
Product Service News

Invivyds PEMGARDA Poised to Shield Immunocompromised Individuals Ahead of Respiratory Virus Season

Published Thu, Sep 12 2024 11:01 AM UTC

In a proactive move to address the rising cases of COVID-19, Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company dedicated to combating serious viral infections, has confirmed its readiness for the upcoming respiratory virus season with its monoclonal antibody treatment, PEMGARDA (pemivibart). Gaining attention in the medical and business communities, PEMGARDA targets ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.53
Price to Sales (Expected) -
Price to Book 1.46
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.16
Working Capital Ratio 6.71
Leverage Ratio (MRQ) 0.21
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.39 $
Revenues (TTM) 0.18 $
Cash Flow (TTM) 0.47 $
Cash 0.5 $
Book Value 0.57 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 478,402
Net Income per Employee (TTM) -879,779
Receivable Turnover Ratio (TTM) 5.01
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.27

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -320.76 %
Net Margin (MRQ) -310.77 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Invivyd Inc's Segments
Product    196.21 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.